Hepatitis Forums
Hepatitis C Main Forums => On Hepatitis C Treatment => Topic started by: julu49 on October 08, 2015, 09:41:24 pm
-
I just read this, and am sending on a little clip. It looks like Gilead is continuing to find better and better hep c drugs
McMahon Publications Anesthesiology Gastroenterology General Surgery Infectious Disease Oncology Pain Medicine Pharmacy Specialty Pharmacy CMEZone
Specialty Pharmacy Continuum
advanced search
Login ID Register | Forgot Password
Password Remember me
Home
Departments
Medical Education
Digital Editions
Archive
Video
Subscribe
About
Advertise
Contact Info
Web Only
POSTED DATE : OCTOBER 8, 2015
printer friendly | email this article
Gilead Close to Pan-Genotypic HCV Drug Submission
by Gina Shaw
Gilead has released top-line data from the four Phase III ASTRAL studies that combined its blockbuster hepatitis C drug sofosbuvir (Sovaldi) and the investigational agent velpatasvir—and the result is a knockout.
In a trial including 624 patients with any of the six strains of hepatitis C virus (HCV), the combination produced a sustained virologic response (SVR) after 12 weeks of therapy in 99% of cases.
In the ASTRAL-1, ASTRAL-2 and ASTRAL-3 trials, a total of 1,035 patients with HCV genotypes 1 to 6 infec-tion received 12 weeks of the sofosbuvir/velpatasvir combination (SOF/VEL). Twenty-one percent of the patients in this group had compensated cirrhosis; 28% had failed prior treatments.
- See more at: http://www.specialtypharmacycontinuum.com/ViewArticle.aspx?ses=ogst&d=Web+Only&d_id=530&i=October+2015&i_id=1230&a_id=33970#sthash.INJV9ieX.dpuf